Advicenne

Advicenne Debt

The Debt of Advicenne (ALDVI.PA) as of Nov 4, 2026 is 19.00 M EUR. In the previous year, Debt was 18.19 M EUR — a change of 4.47% (higher).

Debt

19.00 MEUR

YoY

4.47%

Last updated:

In 2025, Advicenne's total debt was 19.00 M EUR, a 4.47% change from the 18.19 M EUR total debt recorded in the previous year.

The Advicenne Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
419,908.00 EUR
Jan 1, 2019
1.45 M EUR
Jan 1, 2020
13.80 M EUR
Jan 1, 2021
12.54 M EUR
Jan 1, 2022
18.76 M EUR
Jan 1, 2023
18.32 M EUR
Jan 1, 2024
18.19 M EUR
Jan 1, 2025
19.00 M EUR
The Advicenne Debt history
YEARDebtYoY
19.00 MEUR+4.47%
18.19 MEUR-0.73%
18.32 MEUR-2.31%
18.76 MEUR+49.59%
12.54 MEUR-9.13%
13.80 MEUR+849.53%
1.45 MEUR+246.06%
419,908.00EUR-40.16%
701,679.00EUR-78.85%
3.32 MEUR-2.36%
3.40 MEUR+1,162.83%
269,000.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Advicenne Stock analysis

What does Advicenne do? Advicenne SA is a French pharmaceutical company specializing in the development of medications for rare and chronic diseases. The company was founded in 2007 by Dr. Luc-André Granier and is headquartered in Nîmes, France. Business model Advicenne develops its products based on proven technologies in the pharmaceutical industry. The company specializes in the development of medications for rare and chronic diseases, particularly for patients with kidney and metabolic disorders. The company implements a customer-oriented development strategy and is committed to close collaboration with doctors and patients. Advicenne has entered into various partnerships and licensing agreements with other pharmaceutical companies to distribute and further develop its products and technologies worldwide. Divisions Advicenne operates in various business areas, including the development of medications for kidney and metabolic disorders, as well as the marketing of products for patients with chronic diseases. Product portfolio The company currently offers three products: 1. Sibnayal: Sibnayal is a medication for the treatment of kidney diseases. It has been developed to prevent the disease-related loss of potassium in patients with kidney failure. The medication is currently approved for use in a clinical trial. 2. ADV7103: ADV7103 is a medication for the treatment of metabolic disorders. It has been developed to help patients with metabolic disorders such as phenylketonuria (PKU) and hypervalinemia (HV). The medication is currently approved under the name Orladeyo™ and is marketed in collaboration with Daiichi Sankyo Company, Limited. 3. ADV6209: ADV6209 is a medication for the treatment of chronic pain. It is targeted at patients who have not found sufficient pain relief due to chronic pain. The medication is currently in phase II of clinical trials. Advicenne has made significant investments in the development of innovative medications in recent years and has expanded its product pipeline to improve the therapeutic options for patients with rare and chronic diseases. Conclusion Advicenne is an emerging company in the pharmaceutical industry that focuses on the development of medications for rare and chronic diseases. The company aims to improve the lives of patients with its therapies and is committed to close collaboration with doctors and patients. Advicenne has already brought several promising products to market and continues to heavily invest in research and development to improve the therapeutic options for patients with rare and chronic diseases. Advicenne is one of the most popular companies on Eulerpool.

Debt Details

Understanding Advicenne's Debt Structure

Advicenne's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Advicenne's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Advicenne’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Advicenne’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Advicenne stock

Debt of Advicenne is 19.00 M EUR in 2025.

Debt of Advicenne changed from 18.19 M EUR to 19.00 M EUR, representing a 4.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Advicenne since 2006 – with annual values, charts, and detailed analysis.

Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Advicenne historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Advicenne

All Key Metrics — Advicenne